To investigate the role of signaling by the small GTPase Ral, we have generated mice deficient for RalGDS, a guanine nucleotide exchange factor that activates Ral. We show that RalGDS is dispensable for mouse development but plays a substantial role in Ras-induced oncogenesis. Lack of RalGDS results in reduced tumor incidence, size, and progression to malignancy in multistage skin carcinogenesis, and reduced transformation by Ras in tissue culture. RalGDS does not appear to participate in the regulation of cell proliferation, but instead controls survival of transformed cells. Experiments performed in cells isolated from skin tumors suggest that RalGDS mediates cell survival through the activation of the JNK/SAPK pathway. These studies identify RalGDS as a key component in Ras-dependent carcinogenesis in vivo.
Introduction
Rlf, have a Ras binding domain and therefore may be Ras effectors (D'Adamo et al., 1997; de Bruyn et al., 2000 ; Shao and Through their interaction with different effector proteins, small Andres, 2000; Wolthuis and Bos, 1999) . Ral proteins can also GTPases of the Ras family control a wide range of cellular be activated by Ras-independent pathways, via interaction functions, including proliferation, differentiation, survival, and with other small GTPases or in a calcium dependent manner cell movement. Of particular interest in oncogenic signaling by (Hofer et al., 1998; Linnemann et al., 2002; Rosario et al., 2001 ; small GTPases has been the mechanism used by oncogenic Wolthuis et al., 1998) . RalGEF proteins are widely expressed Ras to transform cells. The identification of multiple proteins in mouse tissues, but to date, it is not clear whether different that preferentially interact with active Ras raises the potential members of the family regulate different cellular functions, or if for multiple effector pathways, and has led to a number of they act in a tissue or growth factor-specific manner. Insight studies attempting to elucidate the critical oncogenic signaling into the role of the Ral pathway in Ras-mediated oncogenic pathways downstream of Ras (for recent review, see Repasky transformation came with the observation that dominant negaet al., 2004) .
tive Ral mutants can block Ras-mediated transformation of fiThe activity of small GTPases is modulated by the opposing broblasts in culture (Urano et al., 1996) . Furthermore, the use effects of the guanine nucleotide exchange factors (GEFs), of Ras effector loop mutants capable of activating RalGEF prowhich promote the formation of the active GTP bound state in teins without affecting the activity of Raf or PI3K supports a response to extracellular signals, and the GTPase accelerator role for the Ral pathway in Ras-dependent transformation (Rodproteins (GAPs), which terminate GTPase signaling by facilitatriguez-Viciana et al., 1997; White et al., 1995) . Finally, activated ing GTP hydrolysis to GDP. Interestingly, several GEFs appear versions of RalGEFs can synergize with ERK and PI3K signalto be effector proteins of other small GTPases, thereby providing in transformation assays of cells in culture, and can contribing a link between the activation of one small GTPase and anute to experimental metastasis (Ward et al., 2001) . These results suggest that activation of the Ral pathway alone has a other. The RalGEF family of proteins control the activity of RalA and RalB, and at least three members, RalGDS, Rgl, and Rgl2/ weak oncogenic effect, but can complement the roles of other
S I G N I F I C A N C E
Ras oncogenes are mutated in around 15% of human tumors, so it is important to delineate the oncogenic signaling pathways activated by this GTPase. Ras has multiple effectors, including Raf protein kinases, phosphoinositide-3 kinases, and guanine nucleotide exchange factors for the small GTPases Ral and Rac. While most studies have focused on the role of Raf and PI3-kinase signaling, there is increasing interest in studying the Ral pathway in oncogenesis. Although previous evidence using overexpression and dominant negative approaches in tissue culture has suggested that Ral is involved in Ras-mediated transformation, the results shown here using a mouse model of carcinogenesis provide genetic evidence for the involvement of Ral signaling, and suggest that regulation of cell survival is the mechanism. Shao and Andres, 2000; Wolthuis et al., 1996) . D1 promoter, the c-fos serum response element, and the TATA Northern blot analysis of mouse embryonic fibroblasts binding protein promoter (Henry et al., 2000; Johnson et al., (MEFs) isolated from RalGDS −/− mice shows the presence of a 2000; Murai et al., 1997) . Additionally, Ral has been implicated smaller RalGDS transcript derived from the targeted allele (Figin , 1999) . Aside from its role in cell transformation, the presencoding the predicted protein resulting from the gene ence of Ral GTPases in both the plasma membrane and transtargeting event shows that the truncated RalGDS protein does port vesicles (Bielinski et al., 1993; Feig et al., 1996) suggests not bind to Ras and is also unable to activate Ral (Supplementhat this pathway is involved in membrane trafficking. In fact, tal Data and Figure 1E ). Therefore, if this protein is expressed GTP-bound Ral interacts with Sec5 (Brymora et al., 2001;  in the RalGDS −/− mice, it would not respond to Ras-mediated Moskalenko et al., 2002) , a component of the exocyst complex signaling. In agreement with these data, we found that growth implicated in the delivery of secretory vesicles to specific sites factor-mediated activation of Ral was impaired in MEFs isoin the plasma membrane (Hsu et al., 1999) . The importance of lated from RalGDS −/− embryos compared to cells isolated from Ral in intracellular trafficking is also reflected in its ability to wild-type littermates ( Figure 1F ). Similarly, we observed that regulate endocytosis of EGF and insulin receptors (Nakashima 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment induced et al., 1999). Finally, Ral plays a role in the control of phospholiRal activation in the skin of wild-type animals, but this activapase D activation, suggesting the involvement of this GTPase tion was reduced in RalGDS −/− mice ( Figure 1G ). in the regulation of membrane lipids (Jiang et al., 1995) . HowTo assess the role of RalGDS in Ras-dependent tumor forever, despite the recent advances in our understanding of the mation, we used a well-established chemical carcinogenesis Ral pathway, the physiological consequences of Ral activation protocol where tumors are initiated in epidermal keratinocytes have yet to be resolved.
by topical application of 7,12-dimethylbenz[a]anthracene (DMBA) and subsequently promoted by TPA treatment. This procedure results in the development of benign papillomas with a high Results and discussion incidence of H-Ras mutations (Quintanilla et al., 1986) . Some of these tumors progress to squamous cell carcinomas, which To investigate the role of Ral in oncogenic transformation and can undergo epithelial-mesenchymal transition to spindle cell to study Ral guanine nucleotide exchange factors critical for carcinomas. In RalGDS +/+ mice, tumors appear within 7 weeks this cellular response, we have generated mice deficient in of DMBA application, with 50% of the animals being affected RalGDS, one of the RalGEFs that regulate Ral activity. A by week 8-9. However, in the RalGDS −/− group, we observed targeting vector was designed in which loxP sites flanked exa delay of four weeks in the onset of papillomas ( Figure 2A ). ons 9 to 15 of RalGDS ( Figure 1A ). These exons comprise part
The resistance to tumor development in RalGDS −/− mice was of the catalytic domain of RalGDS and residues involved in the also reflected in the number of papillomas per animal, which binding of the exchange factor to Ras. Embryonic stem cells was reduced by 4-fold compared to wild-type littermates (Figin which the homologous recombination event had occurred ures 2B and 2D). Finally, RalGDS deficiency also affected tuwere transiently transfected with Cre recombinase to excise mor growth, with a significant reduction in the size of the papilthe floxed sequences, resulting in a RalGDS n allele that lacks lomas that developed in RalGDS −/− mice. This impairment in exons 9 to 15 (Figures 1A and 1B) . Cells carrying this allele tumor growth was most evident 15 and 18 weeks after tumor were used for the generation of chimeric mice that transmitted initiation ( Figure 2C ). To examine whether loss of functional the disrupted allele through the germline ( Figure 1C ). InterRalGDS would affect transformation by oncogenic Ras in tiscrossing of RalGDS +/− mice yielded the expected Mendelian sue culture, MEFs isolated from RalGDS +/+ and RalGDS
ratios, indicating that disruption of RalGDS does not result in embryos were first immortalized by infection with a retrovirus embryonic lethality. Moreover, male and female RalGDS −/− encoding SV40 large T oncoprotein, and then pools of immormice are fertile, and no major defects have been observed in talized cells were infected with a retrovirus expressing H-RasV12 any of the organs analyzed, suggesting that RalGDS is disoncoprotein. Figure 2E shows that oncogenic Ras produced pensable during mouse development. Experiments in both 50% fewer foci in RalGDS −/− cells compared with wild-type Drosophila and Xenopus have shown that disruption of the Ral fibroblasts. Reinstatement of RalGDS expression in the imsignaling pathway through expression of Ral mutants results in mortalized RalGDS −/− cells by infection with a retrovirus endevelopmental defects, probably due to a role of Ral in regulatcoding RalGDS restored the induction of transformed foci by ing the actin cytoskeleton (Lebreton et al., 2003; Sawamoto et H-RasV12 to that obtained by infection of wild-type cells. Altoal., 1999) . Although the lack of developmental defects in the gether, these data indicate an important role for RalGDS in RalGDS mutant mice can be due to the differences between Ras-dependent cell transformation and extend previous obsermice, Drosophila, and Xenopus, it is more likely that it reflects vations in the requirement of Ral signaling in Ras-driven oncogenesis to an in vivo setting. different consequences of affecting a single Ral exchange As activated versions of RalGDS have been previously cient mice. DMBA treatment induces formation of adducts in skin DNA that lead to transforming mutations. We tested papilshown to be involved in experimental metastasis, we investigated the role of RalGDS in tumor progression. Tumors dislomas isolated from RalGDS −/− mice and control littermates for the presence of Ras mutations. A to T transversions in Ras sected from the different groups of mice were subjected to histopathological analysis. Papillomas isolated from RalGDS +/+ codon 61 are the most frequent mutations found in two-stage skin carcinogenesis induced papillomas (Quintanilla et al., and RalGDS −/− mice were histologically similar. However, we observed significant differences in the frequency of malignant 1986). This mutation was found in RalGDS −/− papillomas to the same extent as in RalGDS +/+ tumors (data not shown), sugconversion between RalGDS +/+ and RalGDS −/− tumors. Progression from papillomas to malignant carcinomas in RalGDS +/+ gesting that the mechanism of mutagenesis after DMBA treatment is not altered in the absence of RalGDS. mice started within 16 weeks after DMBA initiation, and ultimately, 36% of the tumors progressed to malignancy. In conThis result does not explain the reduced incidence of tumors in RalGDS −/− mice; therefore, we measured the levels of cell trast, no malignant tumors were detected before week 28 in the RalGDS −/− group, and only 9% of the epidermal lesions proliferation and apoptosis in papillomas isolated from the different groups of mice. Animals were injected with 5-bromo-2-had a malignant phenotype (Table 1 ). These data suggest that RalGDS is not only required for Ras-dependent tumor formadeoxyuridine (BrdU) and the level of proliferating cells within the tumors quantified. As shown in Figures 3A and 3B , the tion, but also influences tumor progression.
To determine the reason for a reduced tumor growth in number of proliferating cells is similar for papillomas isolated from the three different genotypes. However, when the levels RalGDS −/− mice, we have analyzed the consequences of PMA and DMBA treatment in the skin of wild-type and RalGDS-defiof cell death in papillomas isolated from RalGDS +/+ and 
RalGDS
−/− mice were examined by TUNEL, a significant differInterestingly, in the light of the known requirement for TNF-α in this model of skin carcinogenesis (Moore et al., 1999) , the abence between animal groups was observed. There was a 4-fold increase in the number of apoptotic cells per millimeter sence of RalGDS did not affect TNF-α-induced apoptosis, suggesting that RalGDS does not function to protect tumor cells of basement membrane in RalGDS −/− papillomas compared to tumors isolated from the RalGDS +/+ mice, while the apoptotic against apoptosis induced by this cytokine (data not shown). Ral signaling has been shown to be a regulator of the JNK/ index was similar in papillomas from heterozygous and wildtype animals ( Figures 3C and 3D) . Consistent with the observa-SAPK signaling pathway (de Ruiter et al., 2000) . The JNK/ SAPK pathway has been shown to be implicated in the regulation that there was a higher rate of apoptosis in RalGDS −/− tumors, we found that a restoration of RalGDS in a tumor cultion of apoptotic cell death, and may have either pro-or antiapoptopic effects, depending on the system being analyzed tured from a RalGDS −/− mouse resulted in a decreased response to the apoptotic stimuli of UV and H 2 O 2 ( Figure 3E ).
(reviewed in Lin, 2003) . Therefore, we investigated whether dif- ferences in the activation of the JNK/SAPK pathway might be results corroborate previous data indicating that the Ral pathway regulates the activity of JNK/SAPK (de Ruiter et al., 2000) . responsible for the enhanced susceptibility to some apoptopic stimuli in RalGDS −/− cells. As shown in Figure 4A , UV To determine whether JNK activation is responsible for the increased survival in RalGDS reconstituted cells, we blocked light, but not TNF-α, induces JNK activation in RalGDS −/− cells, but the activation of this pathway is more sustained when the JNK activation with SP600125, a reversible JNK inhibitor (Bennett et al., 2001) . Following UV light irradiation, JNK inhibition expression of RalGDS is restored, showing that prolonged activation of JNK/SAPK signaling requires RalGDS function. These resulted in an increase in apoptotic cell death to similar levels 
in both RalGDS
−/− and reconstituted cells, showing that in this It is possible that different Ras effectors cooperate in the oncosystem, JNK/SAPK signaling provides a survival signal. Congenic process by regulating different aspects of tumor biology. sistent with the lack of JNK/SAPK activation by TNF-α, Interestingly, genetic ablation of either Tiam1 (Malliri et al. SP600125 had no effect on cell death induced by this cytokine 2002), phospholipase-C epsilon (Bai et al., 2004) , or RalGDS ( Figure 4B ). These results show that RalGDS signaling to JNK/ results in viable mice, whereas ablation of Raf-1 or BRAF leads SAPK activation mediates protection against some apoptotic to death of embryos (Wojnowski et al., 1997; Wojnowski et al. , stimuli, but not others, and argue that the increased apoptosis 1998); these observations raise the possibility that Tiam1, phosthat we see in tumors of RalGDS −/− mice may be due to a pholipase-C epsilon, or RalGDS may be better therapeutic defect in JNK/SAPK activation. In a number of other tumor systargets in cancer, because their inhibition might be less toxic tems, JNK/SAPK signaling has been shown to provide a surthan the inhibition of Raf signaling. vival signal (Hess et al., 2002) , and of particular interest in this
The data we present here suggests that RalGDS is an imporcontext, the JNK/SAPK cascade has been shown to give a surtant effector of Ras-mediated oncogenesis in a mouse model vival signal in mouse skin carcinogenesis protocols (Chen et system. Recent work from Hamad et al. (2002) and Rangarajan al., 2001) . Further experiments will be needed to determine the et al. (2004) suggests that the RalGDS pathway may be more mechanism of JNK/SAPK survival signaling in tumor cells. It critical to transformation by oncogenic Ras in human cells than has been shown that cyclin D1 is a c-jun target gene, and exmouse; however, their studies were all carried out in tissue culpression of this cyclin is also Ral-dependent (Albanese et al., ture systems and may therefore have missed a role for Ral sig-1995; Henry et al., 2000) . Deletion of cyclin D1 in mice results naling in rodent tumor induction in vivo. While our data provide in inhibition of Ras-dependent tumor formation (Robles et al., evidence for RalGDS involvement in Ras-dependent tumor for-1998), a similar phenotype to that observed in the RalGDS −/− mation, further studies will be needed to evaluate the requiremice. Although our results cannot exclude the involvement of ments for RalGDS in other oncogenic pathways not dependent cyclin D1 in the reduced tumorigenesis of RalGDS −/− mice, the on Ras activation; however, preliminary studies in p53 deficient normal levels of cell proliferation in tumors isolated from these mice indicate that ablation of RalGDS does not affect the incianimals ( Figures 3A and 3B ) suggest this is not the case.
dence of tumors (data not shown). Taken together, our results show that RalGDS is required for Ras-induced tumor formation, and suggest that it regulates tu- Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., and Pestell, R.G. (1995) . Transforming p21ras mutants and c-Ets-2 activate the Focus formation assay cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270, Passage 2 MEFs were immortalized by infection with a retrovirus encoding 23589-23597. SV40 large T antigen, and pools of drug-resistant clones containing at least 70-80 independent infection events were isolated. These cell pools were Albright, C.F., Giddings, B.W., Liu, J., Vito, M., and Weinberg, R.A. (1993) . then infected either with an empty vector or with a RalGDS containing retCharacterization of a guanine nucleotide dissociation stimulator for a rasrovirus and drug-resistant pools selected as described above. , et al. (2001) . SP600125, al., 1994; Hennings et al., 1993; van Hogerlinden et al., 1999 
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